Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV

Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV

Bibliographic Details
Main Authors:	Suppiah, R, Judge, A, Batra, R, Javaid, M, Jayne, D, Seo, P, Luqmani, R
Format:	Conference item
Published:	2011

Similar Items

A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULMOATOSIS AND MICROSCOPIC POLYANGIITIS
by: Suppiah, R, et al.
Published: (2010)

The prognostic value of BVAS and VDI in ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)

A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis.
by: Suppiah, R, et al.
Published: (2011)

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
by: Suppiah, R, et al.
Published: (2011)

A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULOMATOSIS AND MICROSCOPIC POLYANGIITIS
by: Suppiah, R, et al.
Published: (2011)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
by: Basu, N, et al.
Published: (2012)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
by: Suppiah, R, et al.
Published: (2011)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
by: Suppiah, R, et al.
Published: (2011)

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire
by: Robson, J, et al.
Published: (2018)

Classification criteria for the anca-associated vasculitides
by: Robson, J, et al.
Published: (2019)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
by: Salisbury, E, et al.
Published: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2004)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
by: Mukhtyar, C, et al.
Published: (2008)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2003)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
by: Salisbury, E, et al.
Published: (2003)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
by: McLaren, J, et al.
Published: (2000)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
by: Luqmani, R, et al.
Published: (2017)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
by: Sara Monti, et al.
Published: (2023-06-01)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
by: Luqmani, R, et al.
Published: (2017)

SP0133 ANCA and their environment
by: Luqmani, R
Published: (2017)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
by: Thomas Daikeler, et al.
Published: (2015-01-01)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
by: Luqmani, R, et al.
Published: (1999)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
by: Arnold, D, et al.
Published: (2010)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Towards diagnostic criteria for the ANCA-associated vasculitides.
by: Luqmani, R
Published: (2007)

A disease-specific patient-reported outcome for ANCA associated vasculitis: scale structure and measurement properties of the AAV- PRO
by: Robson, J, et al.
Published: (2017)

Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist
by: Jennifer J. Y. Lee, et al.
Published: (2019-06-01)

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2011)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis.
by: Luqmani, R, et al.
Published: (2002)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
by: Sara Monti, et al.
Published: (2023-07-01)

THU0306 Prevalence and characteristics of neuropathy in patients with ANCA associated vasculitides: data from the DCVAS study
by: Bischof, A, et al.
Published: (2017)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
by: Luqmani, R
Published: (2013)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
by: Walsh, M, et al.
Published: (2011)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)